66 results
S-1/A
BOLD
Boundless Bio Inc.
21 Mar 24
IPO registration (amended)
6:04am
December 31, 2023 | ||||||||||||
Actual | Pro Forma(1)(3) | Pro Forma As Adjusted(2)(3) | ||||||||||
(in thousands) | (unaudited) | (unaudited) | ||||||||||
Balance Sheet Data: | ||||||||||||
Cash, cash equivalents, and short-term investments | $120,752 | $120,752 | $209,102 | |||||||||
Working capital(4) | 114,845 | 114,845 | 203,195 | |||||||||
Total assets | 129,894 | 129,894 | 218,244 | |||||||||
Total liabilities | 9,359 | 9,359 | 9,359 | |||||||||
Convertible preferred stock | 247,617 | — | — | |||||||||
Accumulated deficit | (136,109) | (136,109) | (136,109) | |||||||||
Total stockholders’ (deficit) equity | (127,082) | 120,535 | 208,885 |
S-1/A
BOLD
Boundless Bio Inc.
21 Mar 24
IPO registration (amended)
6:04am
The following table summarizes on the pro forma as adjusted basis described above, as of December 31, 2023, the differences between the number of shares purchased from us, the total consideration paid to us in cash, and the weighted-average price per share paid by existing stockholders for shares issued prior to this offering and the price to be paid by new investors in this offering. The calculations below are based on an assumed initial public offering price of $16.00 per share, the midpoint of the price range set forth on the cover page of this prospectus, before deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us.
Shares Purchased | Total Consideration | Weighted- Average Price Per Share | ||||||||||||||||||
Number | Percent | Amount | Percent | |||||||||||||||||
Existing stockholders before this offering | 15,989,333 | 71.9 | % | $ | 253,492,717 | 71.7 | % | $ | 15.85 | |||||||||||
New investors participating in this offering | 6,250,000 | 28.1 | % | 100,000,000 | 28.3 | % | $ | 16.00 | ||||||||||||
Total | 22,239,333 | 100.0 | % | $ | 353,492,717 | 100.0 | % | |||||||||||||
S-1/A
BOLD
Boundless Bio Inc.
21 Mar 24
IPO registration (amended)
6:04am
The following table indicates the expenses to be incurred in connection with the offering described in this registration statement, other than underwriting discounts and commissions, all of which will be paid by us. All amounts are estimated except the SEC registration fee, the Financial Industry Regulatory Authority, Inc., or FINRA, filing fee and the Nasdaq Global Select Market listing fee.
Amount Paid or to Be Paid | ||||
SEC registration fee | $ | 18,035 | ||
FINRA filing fee | 18,828 | |||
Nasdaq Global Select Market listing fee | 295,000 | |||
Accountants’ fees and expenses | 950,000 | |||
Legal fees and expenses | 2,955,000 | |||
Transfer Agent’s fees and expenses | 10,000 | |||
Printing and engraving expenses | 385,000 | |||
Miscellaneous | 18,137 | |||
Total expenses | $ | 4,650,000 | ||
S-1/A
BOLD
Boundless Bio Inc.
21 Mar 24
IPO registration (amended)
6:04am
The following tables set forth a summary of our historical financial data as of, and for the periods ended on, the dates indicated. We have derived the summary statements of operations data for the years ended December 31, 2022 and 2023 and the summary balance sheet data as of December 31, 2023 from our audited financial statements included elsewhere in this prospectus. You should read these data together with our financial statements and related notes included elsewhere in this prospectus and the section titled “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” Our historical results for any prior period are not necessarily indicative of our future results.
Year Ended December 31, | ||||||||
2022 | 2023 | |||||||
(in thousands, except per share data) | ||||||||
Statements of Operations Data: | ||||||||
Operating expenses: | ||||||||
Research and development | $ | 37,159 | $ | 42,637 | ||||
General and administrative | 9,310 | 12,159 | ||||||
Total operating expenses | 46,469 | 54,796 | ||||||
Loss from operations | (46,469) | (54,796) | ||||||
Other income (expense), net: | ||||||||
Interest income | 668 | 5,282 | ||||||
Other income (expense) | (100) | 80 | ||||||
Total other income (expense), net | 568 | 5,362 | ||||||
Net loss | $ | (45,901) | $ | (49,434) | ||||
Net loss per common share, basic and diluted(1) | $ | (41.80) | $ | (40.65) | ||||
Weighted-average shares used in net loss per common share calculation, basic and diluted(1) | 1,098 | 1,216 | ||||||
Pro forma net loss per common share, basic and diluted (unaudited)(2) | $ | 3.53 | ||||||
Pro forma weighted-average shares used in pro forma net loss per common share calculation, basic and diluted (unaudited)(2) | 13,990 | |||||||
S-1/A
BOLD
Boundless Bio Inc.
21 Mar 24
IPO registration (amended)
6:04am
The pro forma and pro forma as adjusted information below is illustrative only, and our cash, cash equivalents, and short-term investments and capitalization following the closing of this offering will be adjusted based on the actual initial public offering price and other terms of this offering determined at pricing. You should read this information in conjunction with our financial statements and related notes included in this prospectus and the section titled “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and other financial information contained in this prospectus.
December 31, 2023 | ||||||||||||
Actual | Pro Forma | Pro Forma As Adjusted(1) | ||||||||||
(in thousands, except par value and share data) | (unaudited) | (unaudited) | ||||||||||
Cash, cash equivalents, and short-term investments | $ | 120,752 | $ | 120,752 | $ | 209,102 | ||||||
Convertible preferred stock, $0.0001 par value; 287,446,844 shares authorized, issued, and outstanding, actual; no shares authorized, issued, and outstanding, pro forma, and pro forma as adjusted | $ | 247,617 | $ | — | $ | — | ||||||
Stockholders’ (deficit) equity: | ||||||||||||
Preferred stock, $0.0001 par value; no shares authorized, issued, and outstanding, actual; 70,000,000 shares authorized and no shares issued and outstanding, pro forma and pro forma as adjusted | ||||||||||||
Common stock, $0.0001 par value; 402,600,000 shares authorized, 1,248,493 shares issued and 1,247,012 shares outstanding, excluding 1,481 shares subject to a right of repurchase, actual; 700,000,000 shares authorized, 15,989,333 shares issued, and 15,987,852 outstanding, excluding 1,481 shares subject to a right of repurchase, pro forma; 700,000,000 shares authorized, 22,239,333 shares issued, and 22,237,852 shares outstanding, excluding 1,481 shares subject to a right of repurchase, pro forma as adjusted | — | 2 | 2 | |||||||||
Additional paid-in capital | 8,987 | 256,602 | 344,952 | |||||||||
Accumulated other comprehensive loss | 40 | 40 | 40 | |||||||||
Accumulated deficit | (136,109) | (136,109) | (136,109) | |||||||||
Total stockholders’ (deficit) equity | (127,082) | 120,535 | 208,885 | |||||||||
Total capitalization | $ | 120,535 | $ | 120,535 | $ | 208,885 | ||||||
S-1/A
zollsy6lg1iskn5i3ij
21 Mar 24
IPO registration (amended)
6:04am
S-1/A
617nr1
21 Mar 24
IPO registration (amended)
6:04am
S-1/A
zhika2
21 Mar 24
IPO registration (amended)
6:04am
S-1/A
fsb604kt
21 Mar 24
IPO registration (amended)
6:04am
S-1/A
b771rba
21 Mar 24
IPO registration (amended)
6:04am
S-1/A
dcau 7i2f6r
21 Mar 24
IPO registration (amended)
6:04am
S-1/A
2aprymaxbfqs7dn3u26
21 Mar 24
IPO registration (amended)
6:04am
S-1/A
jtu269
21 Mar 24
IPO registration (amended)
6:04am
S-1/A
kjdca3o7a
21 Mar 24
IPO registration (amended)
6:04am
S-1/A
w3ykxmmg 1d7cak
21 Mar 24
IPO registration (amended)
6:04am
S-1/A
jhl 5y5rcl03lr45
21 Mar 24
IPO registration (amended)
6:04am
S-1/A
j2khovu8xl5k
21 Mar 24
IPO registration (amended)
6:04am
S-1/A
tdz0kgctab5fs7xzpv
21 Mar 24
IPO registration (amended)
6:04am
S-1/A
8glxoiyh2 zk
21 Mar 24
IPO registration (amended)
6:04am
S-1/A
jinn7 dqlnytorf
21 Mar 24
IPO registration (amended)
6:04am